Algiax Pharmaceuticals
Latest round
- Seed
Last raised
- Jul 2012
Total raised
- $5.3M
Investors
- 4
About Algiax Pharmaceuticals
Founded in 2011 and headquartered in Erkrath, Germany, Algiax Pharmaceuticals specializes in therapeutics for chronic neuropathic pain. The company has pivoted to focus on novel GABAA receptor modulators, with its lead product AP-325 currently under development.Algiax Pharmaceuticals GmbH specializes in the development of innovative therapeutics aimed at addressing chronic neuropathic pain and other conditions with unmet medical needs. The company's lead product, AP-325, is a small-molecule, allosteric modulator of the GABAA receptor, designed to provide rapid onset and long-lasting pain relief for patients suffering from chronic neuropathic pain. The mechanism of action is based on enhancing GABAA receptor activity, which helps to inhibit the transmission of pain signals without causing sedation or central nervous system effects, thus reducing dependency risks associated with traditional pain management options. Alongside AP-325, Algiax is exploring a class of compounds known as Thioacrylamide (ThAc) derivatives, which are also aimed at modulating GABAA receptor activity for potential applications in diabetes and chronic pain management.70. The company operates within a clinical-stage biotechnology framework, focusing on the development and potential commercialization of its proprietary products. The transaction structure is likely to include licensing agreements and collaborations with research institutions or pharmaceutical firms, which would facilitate access to broader markets upon product approval. Given the nature of the biotechnology industry, transactions may involve upfront payments, milestone payments contingent on successful clinical trial outcomes, and royalties from product sales. The company is also set to expand its clinical trials into new European markets, including Belgium, France, Spain, and the Czech Republic, aiming for broader market access by the end of 2014. These initiatives reflect Algiax's commitment to enhancing its therapeutic offerings and addressing unmet medical needs in neuropathic pain management.
Who invested in Algiax Pharmaceuticals
4 investors across 1 round
See all investors in Algiax Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jul 20, 2012
Amount
$5.3M
Investors
Questions about Algiax Pharmaceuticals
Who invested in Algiax Pharmaceuticals?
Algiax Pharmaceuticals has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Algiax Pharmaceuticals raised?
Algiax Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Algiax Pharmaceuticals last raise money?
Algiax Pharmaceuticals's most recent round on record is a Seed, in Jul 2012.
What does Algiax Pharmaceuticals do?
Founded in 2011 and headquartered in Erkrath, Germany, Algiax Pharmaceuticals specializes in therapeutics for chronic neuropathic pain.
Where is Algiax Pharmaceuticals headquartered?
Algiax Pharmaceuticals is headquartered in Erkrath, Germany.
Which VCs invest in companies like Algiax Pharmaceuticals?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Algiax Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Algiax Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.